Mast Therapeutics, Inc. (MSTX)

[ddawgpound]

MSTX NEWS 3-6-17

-->Mast Therapeutics Reports Fourth Quarter And Full Year 2016 Financial Results

http://seekingalpha.com/pr/16762681-mast-therapeutics-reports-fourth-quarter-full-year-2016-financial-results

"The Company's net loss for the fourth quarter of 2016 was $6.0 million, or $0.02 per share (basic and diluted), compared to a net loss of $10.2 million, or $0.06 per share (basic and diluted), for the same period in 2015."

-->Mast Therapeutics (MSTX) Confirms Clinical Study Of AIR001 For Treatment Of Chronic Infection In Cystic Fibrosis Patients

https://www.streetinsider.com/dr/news.php?id=12632742&gfv=1

Mast Therapeutics, Inc. (NYSE: MSTX) today reported that its wholly-owned subsidiary, Aires Pharmaceuticals, Inc., has entered into an agreement with the University of Pittsburgh related to a Phase 1/2 open-label safety and proof of concept clinical trial of the Company's lead product candidate, AIR001, for the treatment of Pseudomonas aeruginosa (P. aeruginosa) infection in cystic fibrosis (CF) patients. The study is being conducted by the University of Pittsburgh and the University of Pittsburgh Medical Center. Mast's subsidiary will provide study drug and nebulizers for the study, but no direct financial support.